HT 1067

Drug Profile

HT 1067

Alternative Names: HT-1067

Latest Information Update: 13 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helicon Therapeutics
  • Developer Dart NeuroScience
  • Class Antiparkinsonians
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 13 Apr 2015 Discontinued - Phase-I for Parkinson's disease in USA (unspecified route)
  • 01 Jan 2012 Helicon Therapeutics has been acquired and merged into Dart NeuroScience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top